Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Brain-inspired Computing for Next Generation Generative Artificial Intelligence (SpiNNext)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Challenges
Action type: EIC actions
Countries involved: Germany
Call: GenAI4EU: Creating European Champions in Generative AI (HORIZON-EIC-2025-ACCELERATOR-02, 2025)
Start date: 2025-12-01
End date: 2027-11-30
Duration (months): 24.0
Total project cost (EUR): 3571425.0
EU funding (EUR): 2499997.5
Participants: 1
Project status: SIGNED

As generative AI and large language models drive unprecedented demand for computational resources, traditional GPU-based architectures are reaching their fundamental limits, creating a mounting crisis in energy consumption, cost, and accessibility. Inspired by the human brain's remarkable ability to perform complex computations with minimal energy consumption, we have developed revolutionary AI hardware architecture that redefines the boundaries of computational efficiency. Our SpiNNaker2 chip and SpiNNcloud system translate millions of years of biological evolution into cutting-edge technology, delivering brain-like performance while dramatically reducing energy requirements. Building on our validated SpiNNaker2 technology, we are now introducing SpiNNext—our next-generation chip specifically designed for the emerging demands of modern generative AI. SpiNNext architecture directly addresses the mismatch between increasingly sparse, selective computation patterns in advanced algorithms and traditional dense processing architectures by implementing native hardware support for dynamic sparsity. SpiNNext will enable new possibilities in AI development while maintaining European technological sovereignty. The remarkable energy efficiency of our technology translates directly to significant environmental sustainability through significant reductions in AI-related carbon footprint.

Keywords: multi paradigm ai hardware,foundational ai models,large language models llms,brain inspired architecture,neuromorphic computing,spinnaker technology
Lpool - Revolutionizing AI Datacenters for Sustainable, Cost-Effective and High-Efficiency Computing (LPool)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Germany
Call: EIC Accelerator 2025 - Short application (HORIZON-EIC-2025-ACCELERATOR-01, 2025)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Over the past decade, the on-device performance of CPUs, GPUs, and AI accelerators has improved 100x faster than off-device data movement. This increasingly causes chips to wait for data, lengthening the time to run a job. This data bottleneck thus leads to massive inefficiencies, raising the cost, energy consumption, and carbon footprint to run AI jobs by 57% for datacenter providers and their end-users. ExpectedIT's solution consists of two new proprietary chips: the Large Pool CPU (LP-CPU) chip, its matching Pool chip, and accompanying novel server packaging technology. ExpectedIT will license the intellectual property (IP) for these innovations to chip and datacenter server vendors, enabling the best use of each device's precious off-device data movement. By removing the bottleneck, ExpectedIT's new solution allows AI or other data-intensive applications to run up to 10x faster. By completing the jobs in less time and using fewer hardware resources, LPool will offer datacenters and their end-users up to 2x reduction in costs, energy consumption, and carbon emissions to run a specific job. Our LPool technology will thus significantly impact AI's scalable and sustainable growth for diverse sectors like healthcare diagnostic AI, greentech, enterprise generative AI, and much more. We have validated our technology through over 100K simulation runs of the Verilog code. Based on these promising results, we have attracted the interest of one of the world's leading chip vendors with whom we are in active discussions for them to license the IP for our technology. This project will allow ExpectedIT to complete the engineering of the full chip logic for the Pool chip, the LP-CPU, and server packaging. It will also enable us to double our team size to 30 to carry out these activities, including business developers, to accelerate our go-to-market. Our ambition is to reach 5 licensees and generate over €100 million in royalty revenues by 2031.

Keywords: large pool computer,data centre,computer hardware,high performance computing,server packaging
Improving Clinical Trials Reporting (ICTR)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Sweden,United Kingdom
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2024-09-01
End date: 2026-08-31
Duration (months): 24.0
Total project cost (EUR): 206887.68
EU funding (EUR): 206887.68
Participants: 2
Project status: SIGNED

This proposal will rigorously evaluate three approaches to reducing research waste and publication bias in clinical trials. The findings will provide a firm evidence base to inform efforts to improve the robustness of scientific evidence across the natural and social sciences. Non-publication of results has been estimated to directly waste $85 billion per year in medical research funding. Gaps left by unreported clinical trial results systematically distort the scientific evidence base because negative findings are especially likely to remain unreported. Health systems and insurers are often unable to determine how safe, effective and cost-effective treatments really are, leading to costly procurement missteps and suboptimal and sometimes dangerous patient care. For example, governments worldwide spent over $18 billion on the drug Tamiflu before the previously hidden results of several unsuccessful clinical trials emerged. Today, research waste safeguards for clinical trials are stronger and more advanced than in any other area of research. Multiple approaches to tackling the twin problems of research waste and publication bias have been pioneered in the clinical trials space and are now being adopted in other branches of science. However, it remains unclear which of these measures are effective because their impact has rarely been studied in a systematic and rigorous manner. This undermines efforts to improve the robustness of research across the natural and social sciences. This proposal will fill an important knowledge gap by providing robust evidence on which approaches to reducing research waste and curbing publication bias are effective. Breaking new methodological ground, it will answer three questions: Can stronger funder safeguards reduce research waste? Can sending reminder messages to research institutions reduce research waste? What reminder messages to principal investigators reduce research waste most?

Keywords: research waste publication bias metascience open science clinical trial
STRENGTHENING CAPACITIES AND PROMOTING INNOVATION IN PLANTOMICS AT THE UNIVERSITY OF SFAX (INPLANTOMICS)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Destination: Improved access to Excellence
Action type: Coordination and support actions
Countries involved: Tunisia,Italy,Belgium,Germany
Call: Twinning (HORIZON-WIDERA-2021-ACCESS-03, 2021)
Start date: 2022-12-01
End date: 2026-05-31
Duration (months): 42.0
Total project cost (EUR): 1399261.25
EU funding (EUR): 1399261.25
Participants: 4
Project status: SIGNED

Global climate change is seriously threatening food security. Globally, agriculture must find alternatives for chemical fertilisers that contribute significantly to greenhouse gas emissions- and pesticides. Advanced plant breeding and biotechnology tools offer great opportunities to devise sustainable solutions for future farming. Next-generation sequencing technologies has created new research and innovation potential in genomics and transcriptomics. Also, groundbreaking proteomics, metabolomics and phenomics methods now generate big data beneficial to plant biotechnology and sustainable agriculture. In Tunisia, the Research and Innovation systems are not yet sufficiently developed to fully seize the opportunities made by the availability of omics tools to participate in the necessary transition to a sustainable and climate-neutral agriculture. At the University of Sfax (USF), the lack of strong scientific knowledge in plant omics technologies among researchers and of tailor-made plant technology platforms are major constraints to the development of sustainable and resilient agro-systems. The objective of INPLANTOMICS is to foster scientific excellence and innovation at the USF for the future implementation of the first North African plant biotechnological platform promoting sustainable agriculture and healthy nutrition, at the light of a strong European network and partnership. Equipped with the most advanced omics technologies this platform will greatly improve the transfer of knowledge and innovation to researchers and stakeholders including farmers, breeders, nurserymen and agri-food producers.

Keywords: genomics,transcriptomics,proteomics,sustainable agriculture,phytopathogens,drought,platforms,crop biotechnology,food security,healthy nutrition,resilience to climate change,mobility
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Health
Destination: Unlocking the full potential of new tools, technologies and digital solutions for a healthy society
Action type: Research and Innovation actions
Countries involved: Germany,United Kingdom,Netherlands,Israel,Belgium,Austria
Call: Next generation advanced therapies to treat highly prevalent and high burden diseases with unmet medical needs (HORIZON-HLTH-2021-TOOL-06, 2021)
Start date: 2022-09-01
End date: 2027-02-28
Duration (months): 54.0
Total project cost (EUR): 5824074.75
EU funding (EUR): 5824074.0
Participants: 11
Project status: SIGNED

HEAL will focus on general bottlenecks to induced pluripotent stem cell therapies with a particular focus on heart failure, which remains a major cause of morbidity and mortality with very few treatment options. HLA-homozygous cell line derived cardiomyocyte aggregates offer the prospect of a restorative heart therapy applicable to large patient populations and to overcome economic barriers associated with autologous approaches. By developing solutions for their mass-production and cryopreservation we will enable allogeneic treatment with minimum requirements for immunosuppression. Assays for assessment of immunogenicity will provide data for the development of an artificial intelligence powered algorithm to predict recipients's immune responses for personalised design of immunosuppression protocols. A potency assay to assure product effectiveness will be developed together with assays of tumorigenicity in vitro and in vivo that meet and exceed current regulatory requirements. A genetic integrity pipeline defining the most sensitive assays for rigorous assessment will be developed and a rescue tool in the form of a biallelic suicide gene for programmed cell death will add to the safety toolbox for the therapy. Optimisation of cell-product administration in terms of retention and engraftment, including catheter-based delivery as minimally invasive alternative to surgical application, and assessment of risks of graft-induced arrhythmia will be determined in a pig model. Early dialogues, via established links, to the regulatory authorities will ensure proper development according to GMP requirements. Freedom to operate and licensing strategies with a health technology and infrastructure assessment of European centres will set the scene for approval of the cell product and related assays and protocols for storage and distribution required to progress towards a first in man study of cell-based heart repair.

Keywords: hla homozygous ipsc,immunogenicity,genomic integrity,gene editing,cardiomyocytes,ischemic heart disease,cell therapy,gmp bioprocessing,medicines safety
In situ genetic perturbation of gut bacteria with engineered phage vectors and CRISPR (crInSitu)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Biotechnology and Biosystems E ngineering
Panel description: Biotechnology using all organisms , biotechnology for environment  and food applications, applied plant and animal sciences , bioengineering and synthetic biology , biomass and biofuels , biohazards
Countries involved: France
Call: ERC CONSOLIDATOR GRANTS (ERC-2021-COG, 2021)
Start date: 2022-09-01
End date: 2027-08-31
Duration (months): 60.0
Total project cost (EUR): 1999780.0
EU funding (EUR): 1999780.0
Participants: 1
Project status: SIGNED

Humans live in a symbiotic relationship with trillions of microorganisms that inhabit our bodies and play an important role in health and disease. There is a growing interest in manipulating the microbiome to improve health, yet we currently lack the knowledge and technology to carry out precise interventions. The objective of this proposal is to enable efficient in situ genetic perturbations of bacteria in the gut environment by developing the next generation of synthetic biology tools based on bacteriophage delivery vectors and CRISPR-Cas systems. The first aim is to establish a collection of genetically amenable bacteria of the human gut and the associated vectors. This will be achieved by delivering large combinatorial libraries of vectors to complex bacterial communities followed by the high-throughput identification and isolation of successfully modified bacteria. We will also identify bacterial defense systems against horizontal gene transfer and methods to bypass them. The second aim is to engineer and evolve phage vectors to deliver custom genetic circuits to the microbiome, using two main approaches: the construction of chimeric phage capsids, and the in vivo targeted mutagenesis of phage host range determinants using diversity generating retro-elements. The third aim is to perform in situ genetic perturbations in the gut environment using CRISPR-Cas tools. We will evaluate the efficiency and specificity of our phage vectors in the animal gut environment. Finally we will use our phage vectors to deliver CRISPR-Cas systems to bacteria in the mouse gut and perform forward genetic screens. This will shed light on the genetic requirements for growth in the gut and on the niche occupied by different members of the microbiome. Altogether, the knowledge and technologies developed in this project will be instrumental both to further our understanding of the gut microbiome and for the development of future microbiome targeted therapies.

Keywords: crispr,bacteriophage,microbiome
The Division of Labor in Production Networks (DIVISION)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Individuals, Markets and Organisations
Panel description: Economics, finance , management
Countries involved: Norway
Call: ERC ADVANCED GRANTS (ERC-2023-ADG, 2023)
Start date: 2024-09-01
End date: 2029-08-31
Duration (months): 60.0
Total project cost (EUR): 2277400.0
EU funding (EUR): 2277400.0
Participants: 1
Project status: SIGNED

The division of labor - breaking down work into tasks so that workers can specialize in a subset of tasks - is believed by many economists to be key to economic progress, by providing efficiency gains when producing goods and services. A key feature of the modern economy is that the division of labor is increasingly taking place between firms - in a production network - as firms fragment production along the supply chain, both within and across borders (Johnson and Noguera, 2017). This project aims to provide new frameworks and novel evidence on how deepening production networks shapes the division of labor within and across countries, with particular emphasis on labor market implications of production networks. Specifically, DIVISION will investigate how production networks jointly shape efficiency and equity: What are the economic effects of deepening production networks on efficiency, specialization and growth? And what are the effect on wages, the skill premium (skilled relative to unskilled wages) and earnings inequality? This comprehensive and ambitious analysis includes developing new methods and economic frameworks as well as providing new datasets and novel empirical evidence. Economic growth has slowed down since the 2007-08 global financial crisis, European firms are getting older and less dynamic and economic inequality is increasing in many parts of the world. A rigorous analysis of the role of production networks for efficiency and equity is therefore urgently needed to address today’s main societal challenges.

Keywords: production networks,division of labor,productivity,international trade,global value chains
Applying Reactive Twins to Enhance Monument Information Systems (ARTEMIS)

Framework: Horizon Europe — Excellent Science
Programme: Research infrastructures
Theme: Research infrastructures
Destination: Technology and infrastructures
Action type: Research and Innovation actions
Countries involved: Belgium,France,Italy,United Kingdom,Greece,Slovenia,Portugal,Germany,Ukraine,Spain
Call: AR/VR-empowered digital twins for modelling complex phenomena in new RI application areas (HORIZON-INFRA-2024-TECH-01, 2024)
Start date: 2025-01-01
End date: 2027-12-31
Duration (months): 36.0
Total project cost (EUR): 12988992.57
EU funding (EUR): 11623145.8
Participants: 24
Project status: SIGNED

The ARTEMIS proposal addresses the field of cultural heritage conservation, restoration, safeguard and valorisation by advanced digital technologies, using digital twins and relying on advanced AR/VR technologies. It relies on an extended digital documentation of heritage assets with 3D models incorporated in their digital twins, by implementing services on heritage data that model the behaviour of the real-world assets in different conditions and under the effect of complex external phenomena. The same approach will allow digital experiments testing the effect of activities simulated on the twin. Whenever suitable, the developed services will avail of AR/VR techniques to manage the simulation input and to visualize the outcomes. ARTEMIS will rely on the know-how of participating world-class research infrastructures, making available a huge amount of heritage documentation data, on the contribution of advanced research centres and on the support of specialized technological SMEs. The project will produce a scientific methodology tested on a large number of pilots and will pave the way for innovative applications in heritage research based on digital twins and AR/VR techniques.

Keywords: digital twins,cultural heritage,conservation,safeguard
Determining the mechanisms behind goblet cell dysfunction (GCMech)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology  of ageing , pathophysiology, inter - organ and tissue communication, endocrinology, nutrition,  metabolism, interaction with the microbiome, non -communicable diseases including cancer (and except disorders of the nervous system  and immunity -related diseases)
Countries involved: Israel
Call: ERC STARTING GRANTS (ERC-2021-STG, 2021)
Start date: 2022-02-01
End date: 2027-01-31
Duration (months): 60.0
Total project cost (EUR): 1499361.25
EU funding (EUR): 1499361.0
Participants: 1
Project status: SIGNED

Goblet cells are specialized epithelial cells that secrete mucus and antimicrobial proteins which together form the gut mucus barrier. The mucus barrier protects the host from bacterial invasion and subsequent activation of an inflammatory response, while also providing food for the microbiome. Dysfunction of goblet cells and high penetrability of the mucus barrier are hallmarks of inflammatory bowel diseases (IBD). While the reasons for goblet cell dysfunction are unclear, it is thought that inflammation, host genetics (specifically mutations in autophagy genes) and environmental factors can affect their function. Yet despite their importance, the basic biology of goblet cells is not understood as they are part of a heterogeneous tissue. I developed a new mouse model that allows isolation of ribosomes specifically from goblet cells in vivo, thus revealing the translational response of goblet cells to various conditions. In preliminary studies we found that altering the autophagy process in vivo led to modification of the colonic mucus barrier, alteration of the microbiome and resistance to colitis. We also found that antibiotic treatment, an environmental factor which increases the risk for IBD, altered the mucus barrier and instigates gut inflammation in mice. Our goal is to mechanistically determine how inflammation, autophagy and antibiotics affect goblet cell function during health and IBD. We will 1) define goblet cell function during IBD development in vivo and test if goblet cells fail to regain proper function during remission, leading to relapse. We will also 2) use a novel mouse model of augmented autophagy to determine the role of autophagy in preserving goblet cell function during IBD. Lastly, 3) we will use germ-free mice to reveal the microbiome-dependent and -independent effects of antibiotics on goblet cell function and IBD. Our study will provide new understanding of goblet cell biology and may lead to new therapeutics which target goblet cells.

Keywords: inflammatory bowel diseases,goblet cells,autophagy,antibiotics,microbiota